药股NASH热门# Stock
g*e
1 楼
GLMD, GALT, ICPT, CEMP, RPTP 蓄势待发
Catalyst: GALT top-line result due by the end of July。
To date, Galectin has completed enrollment for the second cohort in an early
stage trial for GR-MD-02 as a potential treatment for NASH, with a top-line
data readout expected by the end of this month. Previously, the company
reported that the initial cohort of patients receiving the drug showed that
it was both safe and well tolerated.
除RPTP本人都持有，相对而言GALT风险最大。
仅供参考信息共享，投资风险自负！Good luck!
Catalyst: GALT top-line result due by the end of July。
To date, Galectin has completed enrollment for the second cohort in an early
stage trial for GR-MD-02 as a potential treatment for NASH, with a top-line
data readout expected by the end of this month. Previously, the company
reported that the initial cohort of patients receiving the drug showed that
it was both safe and well tolerated.
除RPTP本人都持有，相对而言GALT风险最大。
仅供参考信息共享，投资风险自负！Good luck!